Stay informed. See MDA updates on COVID-19

About Us

We're here to transform the lives of people affected by neuromuscular disease.

Muscular Dystrophy Association and MedShr Announce Launch of Professional Neuromuscular Disease Case Discussion Platform

February 17, 2021. The Muscular Dystrophy Association (MDA) announced the launch of a professional discussion group to help support clinical best practice sharing and networking among the neuromuscular disease (NMD) professional community. The discussion group leverages the technology and reach of the global MedShr Platform, a private, professional, verified network for secure clinical discussion between medical professionals (HIPAA, GDPR and GMC compliant) that has over one million members globally.

The MDA MedShr discussion group enables medical professionals to use their own smartphone to share and discuss anonymous clinical cases with colleagues and team members in a private, professional network. Members can comment on existing cases or add their own case studies and polls.

“This group offers a great opportunity for healthcare providers to engage, share best practices and elevate the changing treatment dynamics of NMD with their peers through case discussion,” says Meredith Wilson, vice president of professional and community education for MDA. “MDA will also work with neuromuscular disease experts to craft an ongoing series of educational cases and poll questions to initiate discussion and supplement user-generated content.”

All healthcare professional specialties who manage and treat individuals with NMD or are looking for more information are encouraged to participate and contribute cases and content to the discussion. Download the MedShr App free or register at www.medshr.net and join the neuromuscular disease healthcare professional discussion group at https://medshr.it/neuromuscular.

About the Muscular Dystrophy Association

For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. MDA's MOVR is the first and only data hub that aggregates clinical, genetic, and patient-reported data for multiple neuromuscular diseases to improve health outcomes and accelerate drug development. MDA supports the largest network of multidisciplinary clinics providing best-in-class care at more than 150 of the nation's top medical institutions. Our Resource Center serves the community with one-on-one specialized support, and we offer educational conferences, events, and materials for families and healthcare providers. MDA Advocacy supports equal access for our community, and each year thousands of children and young adults learn vital life skills and gain independence at summer camp and through recreational programs, at no cost to families. During the COVID-19 pandemic, MDA continues to produce virtual events and programming to support our community when in-person events and activities are not possible. MDA’s COVID-19 guidelines and virtual events are posted at mda.org/COVID19. For more information, visit mda.org.

About MedShr

MedShr - the HIPAA, GMC and GDPR compliant App for Doctors – is the world’s leading case discussion platform, enabling clinicians to securely share and discuss clinical images and cases within a global professional network. MedShr is growing rapidly with over 1.4 million members in 190 countries using the platform to learn from each other and to work together to provide better care for their patients.

MedShr has won multiple awards including Facebook’s Social Good App of the Year 2016, United Nations World Summit Award 2017 and ES SME Award in 2018, was a 2019 TechCrunch DT50 Award for Social Impact finalist and named one of the UK’s top 70 high growth technology companies. More recently, MedShr won Best Medical Education Technology Platform 2020 at the UK SME UK Enterprise Awards and Global Brand Awards’ Best in Medical Case Study E-Learning.

MedShr works in partnership with healthcare providers and hundreds of national and specialist medical societies, as well as the NHS, Health Education England and several Royal Colleges. MedShr is now fully live in the USA and building partnerships with US national and specialist medical societies.